<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2025-4-33-40</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-2658</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИ</subject></subj-group></article-categories><title-group><article-title>Hyperhomocysteinemia and endothelial dysfunction in multiple sclerosis</article-title><trans-title-group xml:lang="ru"><trans-title>Гипергомоцистеинемия и эндотелиальная дисфункция при рассеянном склерозе</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2503-355X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дубченко</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dubchenko</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>127644, Москва, ул. Лобненская, 10</p></bio><bio xml:lang="en"><p>10, Lobnenskaya St., Moscow 127644</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2975-4151</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бойко</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Boyko</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алексей Николаевич Бойко - кафедра неврологии, нейрохирургии и медицинской генетики РНИМУ им. Н.И. Пирогова; отдел нейроиммунологии ФЦМН.</p><p>117997, Москва, ул. Островитянова, 1; 117997, Москва, ул. Островитянова, 1, стр. 10</p></bio><bio xml:lang="en"><p>Alexey Nikolaevich Boyko - Department of Neurology, Neurosurgery and Medical Genetics N.I. Pirogov RNRMU; Department of Neuroimmunology FCBN.</p><p>1, Ostrovityanova St., Moscow 117997; 1, Ostrovityanova St., Build. 10, Moscow 117997</p></bio><email xlink:type="simple">boykoan13@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2424-6115</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иванов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivanov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лаборатория регуляции агрегатного состояния крови.</p><p>125315, Москва, ул. Балтийская, 8</p></bio><bio xml:lang="en"><p>Laboratory for the Regulation of Blood Aggregate State.</p><p>8, Baltiyskaya St., Moscow 125315</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0316-8410</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попов</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Popov</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>129110, Москва, ул. Щепкина, 61/2</p></bio><bio xml:lang="en"><p>61/2, Shchepkina St., Moscow 129110</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-6143-9164</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Масленников</surname><given-names>Р. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Maslennikov</surname><given-names>R. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>129110, Москва, ул. Щепкина, 61/2</p></bio><bio xml:lang="en"><p>61/2, Shchepkina St., Moscow 129110</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6939-160X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Круглова</surname><given-names>М. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Kruglova</surname><given-names>M. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра патологии человека.</p><p>119048, Москва, ул. Трубецкая, 8, стр. 2</p></bio><bio xml:lang="en"><p>Department of Human Pathology.</p><p>8, Trubetskaya St., Build. 2, Moscow 119048</p></bio><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Силина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Silina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра патологии человека.</p><p>119048, Москва, ул. Трубецкая, 8, стр. 2</p></bio><bio xml:lang="en"><p>Department of Human Pathology.</p><p>8, Trubetskaya St., Build. 2, Moscow 119048</p></bio><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гусев</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Gusev</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра неврологии, нейрохирургии и медицинской генетики.</p><p>117997, Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>Department of Neurology, Neurosurgery and Medical Genetics.</p><p>10, Lobnenskaya St., Moscow 127644</p></bio><xref ref-type="aff" rid="aff-6"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8077-2905</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кубатиев</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Kubatiev</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лаборатория регуляции агрегатного состояния крови.</p><p>125315, Москва, ул. Балтийская, 8</p></bio><bio xml:lang="en"><p>Laboratory for the Regulation of Blood Aggregate State.</p><p>8, Baltiyskaya St., Moscow 125315</p></bio><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Межокружное отделение рассеянного склероза (МОРС) при ГБУЗ г. Москвы «Городская клиническая больница им. В.В. Вересаева» ДЗМ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Interdistrict Department of Multiple Sclerosis, V.V. Veresaev State Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; ФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Federal Center for Brain and Neurotechnologies, FMBA of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт общей патологии и патофизиологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of General Pathology and Pathophysiology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>M.F. Vladimirsky Moscow Regional Research and Clinical Institute</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>23</day><month>08</month><year>2025</year></pub-date><volume>17</volume><issue>4</issue><fpage>33</fpage><lpage>40</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Dubchenko E.A., Boyko A.N., Ivanov A.V., Popov M.A., Maslennikov R.A., Kruglova M.P., Silina E.V., Gusev E.I., Kubatiev A.A., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Дубченко Е.А., Бойко А.Н., Иванов А.В., Попов М.А., Масленников Р.А., Круглова М.П., Силина Е.В., Гусев Е.И., Кубатиев А.А.</copyright-holder><copyright-holder xml:lang="en">Dubchenko E.A., Boyko A.N., Ivanov A.V., Popov M.A., Maslennikov R.A., Kruglova M.P., Silina E.V., Gusev E.I., Kubatiev A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/2658">https://nnp.ima-press.net/nnp/article/view/2658</self-uri><abstract><p>For a comprehensive study of such a socially significant disease as multiple sclerosis (MS), which occurs predominantly in people of working age and in which neuroinflammation and neurodegeneration go hand in hand, resulting in irreversible damage to the brain and spinal cord, the key point is to decipher the pathophysiological mechanisms of its development and progression. Despite the established relationship between hyperhomocysteinemia and secondary endothelial damage, data on the possible role of homocysteine (Hcy) in disease progression are quite contradictory.</p><sec><title>Objective</title><p>Objective: to investigate the informative value of determining the content of markers of oxidative stress, mitochondrial and endothelial dysfunction in patients with MS.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 63 patients with MS (40 women, 23 men) aged 35 [30; 43] years. The control group consisted of 43 healthy volunteers (22 men, 21 women) aged 37 [32; 44] years. Depending on the therapy received, patients were divided into two groups: those receiving first-line and second-line therapy; patients receiving natalizumab therapy were considered separately. A neurological examination of patients was performed with an assessment of disease severity using the EDSS scale, and the disease progression index was calculated. The following biomarkers were also determined in the blood of patients and volunteers using enzyme-linked immunosorbent assay: intercellular adhesion molecules (ICAM-1), S-adenosylmethionine, S-adenosylhomocysteine, cysteine, cysteinylglycine, glutathione, and Hcy.</p></sec><sec><title>Results</title><p>Results. A statistically significant correlation was found between disease severity (EDSS disability level) and increased Hcy levels. A statistically significant increase in ICAM-1 levels was also found in patients during periods of disease activity (clinical exacerbation, activity according to MRI data), which allows this molecule to be considered as a biomarker of endothelial dysfunction and inflammation.</p></sec><sec><title>Conclusion</title><p>Conclusion. The results of the study indicate the need to continue studying the pathophysiological causes of the onset and progression of MS, further identifying new biomarkers for predicting the course of MS, and evaluating the effectiveness of drugs that alter the course of MS.</p></sec></abstract><trans-abstract xml:lang="ru"><p>Для всеобъемлющего изучения такого социально значимого заболевания, возникающего в подавляющем большинстве случаев у лиц трудоспособного возраста, как рассеянный склероз (РС), при котором нейровоспаление и нейродегенерация идут рука об руку, вследствие чего необратимо поражается вещество головного и спинного мозга, ключевым моментом является расшифровка патофизиологических механизмов развития и прогрессирования. Несмотря на установленную взаимосвязь гипергомоцистеинемии и вторичного поражения эндотелия, данные о возможной роли гомоцистеина (Hcy) в прогрессировании заболевания достаточно противоречивы.</p><p>Цель исследования – изучение информативности определения содержания маркеров оксидативного стресса, митохондриальной и эндотелиальной дисфункции у пациентов с РС.</p><sec><title>Материал и методы</title><p>Материал и методы. В исследование были включены 63 пациента с РС (40 женщин, 23 мужчины) в возрасте 35 [30; 43] лет. Контрольную группу составили 43 здоровых добровольца (22 мужчины, 21 женщина) в возрасте 37 [32; 44] лет. В зависимости от принимаемой терапии пациенты были разделены на две группы: принимающих терапию первой и второй линии; отдельно рассматривались пациенты, получающие терапию натализумабом. Проводился неврологический осмотр пациентов с оценкой тяжести заболевания по шкале EDSS, рассчитывался индекс прогрессирования заболевания. Также в крови пациентов и добровольцев методом иммуноферментного анализа определялись следующие биомаркеры: молекулы межклеточной адгезии (ICAM-1), S-аденозилметионин, S-аденозилгомоцистеин, цистеин, цистеинилглицин, глутатион, Hcy.</p></sec><sec><title>Результаты</title><p>Результаты. Была выявлена статистически значимая корреляция между тяжестью заболевания (уровень инвалидизации по шкале EDSS) и повышением уровня Hcy. Также было установлено статистически значимое повышение уровня ICAM-1 у пациентов в период активности заболевания (клиническое обострение, активность по данным МРТ), что позволяет рассматривать данную молекулу в качестве биомаркера эндотелиальной дисфункции и воспаления.</p></sec><sec><title>Заключение</title><p>Заключение. Результаты исследования свидетельствуют о необходимости продолжения изучения патофизиологических причин начала и прогрессирования РС, дальнейшего выявления новых биомаркеров для прогнозирования течения РС, оценки эффективности препаратов, изменяющих течение РС.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>рассеянный склероз</kwd><kwd>гомоцистеин</kwd><kwd>гипергомоцистеинемия</kwd><kwd>эндотелиальная дисфункция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>multiple sclerosis</kwd><kwd>homocysteine</kwd><kwd>hyperhomocysteinemia</kwd><kwd>endothelial dysfunction</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование не имело спонсорской поддержки</funding-statement><funding-statement xml:lang="en">The investigation has not been sponsored</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Jakimovski D, Bittner S, Zivadinov R, et al. Multiple sclerosis. Lancet. 2024 Jan 13;403(10422):183-202. doi: 10.1016/S0140-6736(23)01473-3. Epub 2023 Nov 7.</mixed-citation><mixed-citation xml:lang="en">Jakimovski D, Bittner S, Zivadinov R, et al. Multiple sclerosis. Lancet. 2024 Jan 13;403(10422):183-202. doi: 10.1016/S0140-6736(23)01473-3. Epub 2023 Nov 7.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации. Рассеянный склероз. Москва; 2022.</mixed-citation><mixed-citation xml:lang="en">Clinical guidelines. Multiple sclerosis. Moscow; 2022 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Aliyu M, Zohora FT, Ceylan A, et al. Immunopathogenesis of multiple sclerosis: molecular and cellular mechanisms and new immunotherapeutic approaches. Immunopharmacol Immunotoxicol. 2024 Jun;46(3):355-77. doi: 10.1080/08923973.2024.2330642. Epub 2024 Apr 18.</mixed-citation><mixed-citation xml:lang="en">Aliyu M, Zohora FT, Ceylan A, et al. Immunopathogenesis of multiple sclerosis: molecular and cellular mechanisms and new immunotherapeutic approaches. Immunopharmacol Immunotoxicol. 2024 Jun;46(3):355-77. doi: 10.1080/08923973.2024.2330642. Epub 2024 Apr 18.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Amezcua L. Progressive Multiple Sclerosis. Continuum (Minneap Minn). 2022 Aug 1;28(4):1083-103. doi: 10.1212/CON.0000000000001157</mixed-citation><mixed-citation xml:lang="en">Amezcua L. Progressive Multiple Sclerosis. Continuum (Minneap Minn). 2022 Aug 1;28(4):1083-103. doi: 10.1212/CON.0000000000001157</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kavaliunas A, Danylaite Karrenbauer V, Hillert J. Socioeconomic consequences of multiple sclerosis – A systematic literature review. Acta Neurol Scand. 2021 Jun;143(6):587-601. doi: 10.1111/ane.13411. Epub 2021 Mar 22.</mixed-citation><mixed-citation xml:lang="en">Kavaliunas A, Danylaite Karrenbauer V, Hillert J. Socioeconomic consequences of multiple sclerosis – A systematic literature review. Acta Neurol Scand. 2021 Jun;143(6):587-601. doi: 10.1111/ane.13411. Epub 2021 Mar 22.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kuhlmann T, Moccia M, Coetzee T, et al; International Advisory Committee on Clinical Trials in Multiple Sclerosis. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023 Jan;22(1):78-88. doi: 10.1016/S1474-4422(22)00289-7. Epub 2022 Nov 18.</mixed-citation><mixed-citation xml:lang="en">Kuhlmann T, Moccia M, Coetzee T, et al; International Advisory Committee on Clinical Trials in Multiple Sclerosis. Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol. 2023 Jan;22(1):78-88. doi: 10.1016/S1474-4422(22)00289-7. Epub 2022 Nov 18.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Rida Zainab S, Zeb Khan J, Khalid Tipu M, et al. A review on multiple sclerosis: Unravelling the complexities of pathogenesis, progression, mechanisms and therapeutic innovations. Neuroscience. 2025 Feb 16;567:133-49. doi: 10.1016/j.neuroscience.2024.12.029. Epub 2024 Dec 19.</mixed-citation><mixed-citation xml:lang="en">Rida Zainab S, Zeb Khan J, Khalid Tipu M, et al. A review on multiple sclerosis: Unravelling the complexities of pathogenesis, progression, mechanisms and therapeutic innovations. Neuroscience. 2025 Feb 16;567:133-49. doi: 10.1016/j.neuroscience.2024.12.029. Epub 2024 Dec 19.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Milo R, Korczyn AD, Manouchehri N, Stüve O. The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis. Mult Scler. 2020 Jul;26(8):876-86. doi: 10.1177/1352458519886943. Epub 2019 Nov 4.</mixed-citation><mixed-citation xml:lang="en">Milo R, Korczyn AD, Manouchehri N, Stüve O. The temporal and causal relationship between inflammation and neurodegeneration in multiple sclerosis. Mult Scler. 2020 Jul;26(8):876-86. doi: 10.1177/1352458519886943. Epub 2019 Nov 4.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ramos-Gonzalez EJ, Bitzer-Quintero OK, Ortiz G, et al. Relationship between inflammation and oxidative stress and its effect on multiple sclerosis. Neurologia (Engl Ed). 2024 Apr;39(3):292-301. doi: 10.1016/j.nrleng.2021.10.010</mixed-citation><mixed-citation xml:lang="en">Ramos-Gonzalez EJ, Bitzer-Quintero OK, Ortiz G, et al. Relationship between inflammation and oxidative stress and its effect on multiple sclerosis. Neurologia (Engl Ed). 2024 Apr;39(3):292-301.  doi: 10.1016/j.nrleng.2021.10.010</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Dubchenko E, Ivanov A, Spirina N, et al. Hyperhomocysteinemia and Endothelial Dysfunction in Multiple Sclerosis. Brain Sci. 2020 Sep 16;10(9):637. doi: 10.3390/brainsci10090637</mixed-citation><mixed-citation xml:lang="en">Dubchenko E, Ivanov A, Spirina N, et al. Hyperhomocysteinemia and Endothelial Dysfunction in Multiple Sclerosis. Brain Sci. 2020 Sep 16;10(9):637. doi: 10.3390/brainsci10090637</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Li X, Yuan J, Han J, Hu W. Serum levels of Homocysteine, Vitamin B12 and Folate in Patients with Multiple Sclerosis: an Updated Meta-Analysis. Int J Med Sci. 2020 Mar 5;17(6):751-61. doi: 10.7150/ijms.42058</mixed-citation><mixed-citation xml:lang="en">Li X, Yuan J, Han J, Hu W. Serum levels of Homocysteine, Vitamin B12 and Folate in Patients with Multiple Sclerosis: an Updated Meta-Analysis. Int J Med Sci. 2020 Mar 5;17(6):751-61. doi: 10.7150/ijms.42058</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Jamroz-Wisniewska A., Beltowski J., Wojcicka G., et al. Cladribine Treatment Improved Homocysteine Metabolism and Increased Total Serum Antioxidant Activity in Secondary Progressive Multiple Sclerosis Patients. Oxid Med Cell Longev. 2020;2020:1654754. doi: 10.1155/2020/1654754</mixed-citation><mixed-citation xml:lang="en">Jamroz-Wisniewska A., Beltowski J., Wojcicka G., et al. Cladribine Treatment Improved Homocysteine Metabolism and Increased Total Serum Antioxidant Activity in Secondary Progressive Multiple Sclerosis Patients. Oxid Med Cell Longev. 2020;2020:1654754. doi: 10.1155/2020/1654754</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu X, Wei J, Li J, et al. The causal role of homocysteine in multiple diseases: a systematic review of Mendelian randomization studies. Nutr Metab (Lond). 2025 May 20;22(1):45. doi: 10.1186/s12986-025-00933-0</mixed-citation><mixed-citation xml:lang="en">Zhu X, Wei J, Li J, et al. The causal role of homocysteine in multiple diseases: a systematic review of Mendelian randomization studies. Nutr Metab (Lond). 2025 May 20;22(1):45. doi: 10.1186/s12986-025-00933-0</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Mititelu RR, Albu CV, Bacanoiu MV, et al. Homocysteine as a Predictor Tool in Multiple Sclerosis. Discoveries (Craiova). 2021 Sep 28;9(3):e135. doi: 10.15190/d.2021.14</mixed-citation><mixed-citation xml:lang="en">Mititelu RR, Albu CV, Bacanoiu MV, et al. Homocysteine as a Predictor Tool in Multiple Sclerosis. Discoveries (Craiova). 2021 Sep 28;9(3):e135. doi: 10.15190/d.2021.14</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Jakubowski H, Witucki L. Homocysteine Metabolites, Endothelial Dysfunction, and Cardiovascular Disease. Int J Mol Sci. 2025 Jan 16;26(2):746. doi: 10.3390/ijms26020746</mixed-citation><mixed-citation xml:lang="en">Jakubowski H, Witucki L. Homocysteine Metabolites, Endothelial Dysfunction, and Cardiovascular Disease. Int J Mol Sci. 2025 Jan 16;26(2):746. doi: 10.3390/ijms26020746</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Smith AD, Refsum H. Homocysteine – from disease biomarker to disease prevention. J Intern Med. 2021 Oct;290(4):826-54. doi: 10.1111/joim.13279. Epub 2021 Apr 6.</mixed-citation><mixed-citation xml:lang="en">Smith AD, Refsum H. Homocysteine – from disease biomarker to disease prevention. J Intern Med. 2021 Oct;290(4):826-54. doi: 10.1111/joim.13279. Epub 2021 Apr 6.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">McCaddon A, Miller JW. Homocysteine – a retrospective and prospective appraisal. Front Nutr. 2023 Jun 13;10:1179807. doi: 10.3389/fnut.2023.1179807</mixed-citation><mixed-citation xml:lang="en">McCaddon A, Miller JW. Homocysteine – a retrospective and prospective appraisal. Front Nutr. 2023 Jun 13;10:1179807. doi: 10.3389/fnut.2023.1179807</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Cao X, Wang T, Mu G, et al. Dysregulated homocysteine metabolism and cardiovascular disease and clinical treatments. Mol Cell Biochem. 2025 May 10. doi: 10.1007/s11010025-05284-1. Epub ahead of print.</mixed-citation><mixed-citation xml:lang="en">Cao X, Wang T, Mu G, et al. Dysregulated homocysteine metabolism and cardiovascular disease and clinical treatments. Mol Cell Biochem. 2025 May 10. doi: 10.1007/s11010025-05284-1. Epub ahead of print.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Li X, Zhou Z, Tao Y, et al. Linking homocysteine and ferroptosis in cardiovascular disease: insights and implications. Apoptosis. 2024 Dec;29(11-12):1944-58. doi: 10.1007/s10495024-01999-6. Epub 2024 Jul 23.</mixed-citation><mixed-citation xml:lang="en">Li X, Zhou Z, Tao Y, et al. Linking homocysteine and ferroptosis in cardiovascular disease: insights and implications. Apoptosis. 2024 Dec;29(11-12):1944-58. doi: 10.1007/s10495024-01999-6. Epub 2024 Jul 23.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Cordaro M, Siracusa R, Fusco R, et al. Involvements of Hyperhomocysteinemia in Neurological Disorders. Metabolites. 2021 Jan 6;11(1):37. doi: 10.3390/metabo11010037</mixed-citation><mixed-citation xml:lang="en">Cordaro M, Siracusa R, Fusco R, et al. Involvements of Hyperhomocysteinemia in Neurological Disorders. Metabolites. 2021 Jan 6;11(1):37. doi: 10.3390/metabo11010037</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ansari R, Mahta A, Mallack E, Luo JJ. Hyperhomocysteinemia and neurologic disorders: a review. J Clin Neurol. 2014 Oct;10(4):281-8. doi: 10.3988/jcn.2014.10.4.281. Epub 2014 Oct 6. Erratum in: J Clin Neurol. 2015 Jan;11(1):106. doi: 10.3988/jcn.2015.11.1.106</mixed-citation><mixed-citation xml:lang="en">Ansari R, Mahta A, Mallack E, Luo JJ. Hyperhomocysteinemia and neurologic disorders: a review. J Clin Neurol. 2014 Oct;10(4):281-8. doi: 10.3988/jcn.2014.10.4.281. Epub 2014 Oct 6. Erratum in: J Clin Neurol. 2015 Jan;11(1):106. doi: 10.3988/jcn.2015.11.1.106</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Dardiotis E, Arseniou S, Sokratous M, et al. Vitamin B12, folate, and homocysteine levels and multiple sclerosis: A meta-analysis. Mult Scler Relat Disord. 2017 Oct;17:190-7. doi: 10.1016/j.msard.2017.08.004. Epub 2017 Aug 16.</mixed-citation><mixed-citation xml:lang="en">Dardiotis E, Arseniou S, Sokratous M, et al. Vitamin B12, folate, and homocysteine levels and multiple sclerosis: A meta-analysis. Mult Scler Relat Disord. 2017 Oct;17:190-7. doi: 10.1016/j.msard.2017.08.004. Epub 2017 Aug 16.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kararizou E, Paraskevas G, Triantafyllou N, et al. Plasma homocysteine levels in patients with multiple sclerosis in the Greek population. J Chin Med Assoc. 2013;76:611-4. doi: 10.1016/j.jcma.2013.07.002</mixed-citation><mixed-citation xml:lang="en">Kararizou E, Paraskevas G, Triantafyllou N, et al. Plasma homocysteine levels in patients with multiple sclerosis in the Greek population. J Chin Med Assoc. 2013;76:611-4. doi: 10.1016/j.jcma.2013.07.002</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Fahmy EM, Elfayoumy NM, Abdelalim AM, et al. Relation of serum levels of homocysteine, vitamin B12 and folate to cognitive functions in multiple sclerosis patients. Int J Neurosci. 2018 Sep;128(9):835-41. doi: 10.1080/00207454.2018.1435538. Epub 2018 Feb 21.</mixed-citation><mixed-citation xml:lang="en">Fahmy EM, Elfayoumy NM, Abdelalim AM, et al. Relation of serum levels of homocysteine, vitamin B12 and folate to cognitive functions in multiple sclerosis patients. Int J Neurosci. 2018 Sep;128(9):835-41. doi: 10.1080/00207454.2018.1435538. Epub 2018 Feb 21.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Imeni Kashan A, Mirzaasgari Z, Nouri Shirazi S. Relationship between serum levels of folic acid and homocysteine with cognitive impairment in patients diagnosed with multiple sclerosis. Medicine (Baltimore). 2024 Jul 12;103(28):e38680. doi: 10.1097/MD.0000000000038680</mixed-citation><mixed-citation xml:lang="en">Imeni Kashan A, Mirzaasgari Z, Nouri Shirazi S. Relationship between serum levels of folic acid and homocysteine with cognitive impairment in patients diagnosed with multiple sclerosis. Medicine (Baltimore). 2024 Jul 12;103(28):e38680. doi: 10.1097/MD.0000000000038680</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Adamczyk-Sowa M, Sowa P, Adamczyk J, et al. Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone. J Physiol Pharmacol. 2016;67:235-42.</mixed-citation><mixed-citation xml:lang="en">Adamczyk-Sowa M, Sowa P, Adamczyk J, et al. Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone. J Physiol Pharmacol. 2016;67:235-42.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Ivanov AV, Popov MA, Aleksandrin VV, et al. Determination of glutathione in blood via capillary electrophoresis with pH-mediated stacking. Electrophoresis. 2022 Oct;43(1819):1859-70. doi: 10.1002/elps.202200119. Epub 2022 Jul 29. Erratum in: Electrophoresis. 2022 Dec;43(23-24):2466. doi: 10.1002/elps.202270142</mixed-citation><mixed-citation xml:lang="en">Ivanov AV, Popov MA, Aleksandrin VV, et al. Determination of glutathione in blood via capillary electrophoresis with pH-mediated stacking. Electrophoresis. 2022 Oct;43(1819):1859-70. doi: 10.1002/elps.202200119. Epub 2022 Jul 29. Erratum in: Electrophoresis. 2022 Dec;43(23-24):2466. doi: 10.1002/elps.202270142</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Ivanov AV, Dubchenko EA, Kruglova MP, et al. Determination of S-adenosylmethionine and S-adenosylhomocysteine in blood plasma by UPLC with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Aug 15;1124:366-74. doi: 10.1016/j.jchromb.2019.06.032. Epub 2019 Jun 27.</mixed-citation><mixed-citation xml:lang="en">Ivanov AV, Dubchenko EA, Kruglova MP, et al. Determination of S-adenosylmethionine and S-adenosylhomocysteine in blood plasma by UPLC with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Aug 15;1124:366-74. doi: 10.1016/j.jchromb.2019.06.032. Epub 2019 Jun 27.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Moghaddasi M, Mamarabadi M, Mohebi N, et al. Homocysteine, vitamin B12 and folate levels in Iranian patients with Multiple Sclerosis: a case control study. Clin Neurol Neurosurg. 2013 Sep;115(9):1802-5. doi: 10.1016/j.clineuro.2013.05.007. Epub 2013 Jun 10.</mixed-citation><mixed-citation xml:lang="en">Moghaddasi M, Mamarabadi M, Mohebi N, et al. Homocysteine, vitamin B12 and folate levels in Iranian patients with Multiple Sclerosis: a case control study. Clin Neurol Neurosurg. 2013 Sep;115(9):1802-5. doi: 10.1016/j.clineuro.2013.05.007. Epub 2013 Jun 10.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Teunissen CE, Killestein J, Kragt JJ, et al. Serum homocysteine levels in relation to clinical progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1349-53. doi: 10.1136/jnnp.2008.151555. Epub 2008 Aug 1.</mixed-citation><mixed-citation xml:lang="en">Teunissen CE, Killestein J, Kragt JJ, et al. Serum homocysteine levels in relation to clinical progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2008 Dec;79(12):1349-53. doi: 10.1136/jnnp.2008.151555. Epub 2008 Aug 1.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Guzel I, Mungan S, Oztekin ZN, Ak F. Is there an association between the Expanded Disability Status Scale and inflammatory markers in multiple sclerosis? J Chin Med Assoc. 2016 Feb;79(2):54-7. doi: 10.1016/j.jcma.2015.08.010. Epub 2015 Nov 14.</mixed-citation><mixed-citation xml:lang="en">Guzel I, Mungan S, Oztekin ZN, Ak F. Is there an association between the Expanded Disability Status Scale and inflammatory markers in multiple sclerosis? J Chin Med Assoc. 2016 Feb;79(2):54-7. doi: 10.1016/j.jcma.2015.08.010. Epub 2015 Nov 14.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Jasiak-Zatonska M, Pietrzak A, Wyciszkiewicz A, et al. Different blood-brainbarrier disruption profiles in multiple sclerosis, neuromyelitis optica spectrum disorders, and neuropsychiatric systemic lupus erythematosus. Neurol Neurochir Pol. 2022;56(3):246-55. doi: 10.5603/PJNNS.a2022.0013. Epub 2022 Feb 4.</mixed-citation><mixed-citation xml:lang="en">Jasiak-Zatonska M, Pietrzak A, Wyciszkiewicz A, et al. Different blood-brainbarrier disruption profiles in multiple sclerosis, neuromyelitis optica spectrum disorders, and neuropsychiatric systemic lupus erythematosus. Neurol Neurochir Pol. 2022;56(3):246-55. doi: 10.5603/PJNNS.a2022.0013. Epub 2022 Feb 4.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Hartung HP, Michels M, Reiners K, et al. Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis. Neurology. 1993 Nov;43(11):2331-5. doi: 10.1212/wnl.43.11.2331</mixed-citation><mixed-citation xml:lang="en">Hartung HP, Michels M, Reiners K, et al. Soluble ICAM-1 serum levels in multiple sclerosis and viral encephalitis. Neurology. 1993 Nov;43(11):2331-5. doi: 10.1212/wnl.43.11.2331</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Sharief MK, Noori MA, Ciardi M, et al. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage. J Neuroimmunol. 1993 Mar;43(1-2):15-21. doi: 10.1016/0165-5728(93)90070-f</mixed-citation><mixed-citation xml:lang="en">Sharief MK, Noori MA, Ciardi M, et al. Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage. J Neuroimmunol. 1993 Mar;43(1-2):15-21. doi: 10.1016/0165-5728(93)90070-f</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Alexander JS, Chervenak R, Weinstock-Guttman B, et al. Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A casecontrol, cross sectional study with conventional MRI and advanced iron content imaging outcomes. J Neurol Sci. 2015 Aug 15;355(1-2):84-9. doi: 10.1016/j.jns.2015.05.027. Epub 2015 May 28.</mixed-citation><mixed-citation xml:lang="en">Alexander JS, Chervenak R, Weinstock-Guttman B, et al. Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A casecontrol, cross sectional study with conventional MRI and advanced iron content imaging outcomes. J Neurol Sci. 2015 Aug 15;355(1-2):84-9. doi: 10.1016/j.jns.2015.05.027. Epub 2015 May 28.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Singhal NK, Li S, Arning E, et al. Changes in Methionine Metabolism and Histone H3 Trimethylation Are Linked to Mitochondrial Defects in Multiple Sclerosis. J Neurosci. 2015 Nov 11;35(45):15170-86. doi: 10.1523/JNEUROSCI.4349-14.2015</mixed-citation><mixed-citation xml:lang="en">Singhal NK, Li S, Arning E, et al. Changes in Methionine Metabolism and Histone H3 Trimethylation Are Linked to Mitochondrial Defects in Multiple Sclerosis. J Neurosci. 2015 Nov 11;35(45):15170-86. doi: 10.1523/JNEUROSCI.4349-14.2015</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Spurgeon S, Yu M, Phillips JD, Epner EM. Cladribine: not just another purine analogue? Expert Opin Investig Drugs. 2009 Aug;18(8):1169-81. doi: 10.1517/13543780903071038</mixed-citation><mixed-citation xml:lang="en">Spurgeon S, Yu M, Phillips JD, Epner EM. Cladribine: not just another purine analogue? Expert Opin Investig Drugs. 2009 Aug;18(8):1169-81. doi: 10.1517/13543780903071038</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Li H, Lu H, Tang W, Zuo J. Targeting methionine cycle as a potential therapeutic strategy for immune disorders. Expert Opin Ther Targets. 2017 Aug 23:1-17. doi: 10.1080/14728222.2017.1370454. Epub ahead of print.</mixed-citation><mixed-citation xml:lang="en">Li H, Lu H, Tang W, Zuo J. Targeting methionine cycle as a potential therapeutic strategy for immune disorders. Expert Opin Ther Targets. 2017 Aug 23:1-17. doi: 10.1080/14728222.2017.1370454. Epub ahead of print.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Bystricka Z, Laubertova L, Durfinova M, Paduchova Z. Methionine metabolism and multiple sclerosis. Biomarkers. 2017 Dec;22(8):747-54. doi: 10.1080/1354750X.2017.1334153. Epub 2017 Jun 6.</mixed-citation><mixed-citation xml:lang="en">Bystricka Z, Laubertova L, Durfinova M, Paduchova Z. Methionine metabolism and multiple sclerosis. Biomarkers. 2017 Dec;22(8):747-54. doi: 10.1080/1354750X.2017.1334153. Epub 2017 Jun 6.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
